Cellular Therapy Comes to Main Street: A New Era for Cancer Treatment

OMAHA, Neb. – September 01, 2026 – A quiet but monumental shift is underway in the war on cancer. The Foundation for the Accreditation of Cellular Therapy (FACT) has announced that Tennessee Oncology, a community-based practice, has become the first of its kind to earn accreditation for administering complex immune effector cell (IEC) therapies. While the announcement may seem like procedural news, its implications are profound, signaling the beginning of the end for an era where life-saving treatments like CAR T-cell therapy were confined to the ivory towers of major academic medical centers. This milestone isn't just about one clinic; it's about redrawing the map of advanced cancer care in America.

For years, CAR T-cell therapy has existed as a frustrating paradox: a revolutionary treatment capable of sending aggressive blood cancers into remission, yet inaccessible to the vast majority of patients who could benefit. The logistical and financial hurdles have been immense. Treatment required patients to relocate for weeks or months to one of a few dozen specialized university hospitals, creating a grueling ordeal of travel, separation from family, and immense financial strain. This geographic lottery has systematically widened healthcare disparities, leaving patients in rural or less affluent areas with fewer options. This new accreditation marks the first concrete step in dismantling that inequitable system.

Bridging the Great Divide in Advanced Cancer Care

The core challenge of cellular therapy has always been balancing its power with its risks. These "living drugs," which involve engineering a patient's own immune cells to fight cancer, can trigger severe side effects that require expert management. This necessity concentrated expertise and infrastructure in large, well-funded academic institutions, inadvertently creating a bottleneck that limited patient access. Research has consistently shown that distance to a treatment center is a primary barrier, with many eligible patients forgoing therapy simply because the journey is too arduous.

"A strategic imperative of FACT is to help expand eligible patient access to safe and quality-based CAR T therapies throughout America's communities," stated Dr. Navneet Majhail, who became FACT President in January. This statement is not mere rhetoric; it represents a fundamental change in philosophy for the organization that sets the global standard for cellular therapy.

The new model championed by FACT and pioneered by Tennessee Oncology aims to bring the treatment to the patient, not the other way around. By enabling qualified community cancer centers to administer these therapies, the system can alleviate the immense travel and financial burdens that currently prevent thousands from accessing care. This decentralization promises to improve treatment adherence, reduce patient and caregiver burnout, and begin to close the glaring access gaps tied to geography and socioeconomic status. It democratizes hope, making a cutting-edge therapy a viable option for a far broader population.

Redefining the Gold Standard: Quality Meets Accessibility

The critical question is whether decentralization can be achieved without compromising the rigorous safety standards that define these complex therapies. FACT's answer is a resounding yes, delivered through its meticulously developed "FACT Standards for Immune Effector Cells in the Community Clinical Setting." Published in November 2025 after a consensus process involving experts from both academic and community settings, these standards are not a diluted version of the international gold standard but are instead "fit for purpose."

They maintain a non-negotiable foundation in quality and patient safety while adapting requirements to the operational realities of a community clinic. A key provision, for instance, is that while the clinic itself doesn't need to be a hospital, it must have a robust, formalized partnership with a nearby hospital capable of managing any serious treatment-related complications. This creates a safety net that ensures patients receive immediate, high-level care if needed, replicating the integrated safety model of an academic center through strategic collaboration.

"FACT is committed to expanding patient access and working with community oncology programs to ensure that care happens safely and with quality at the forefront," said FACT CEO David Schmahl. "This first accreditation demonstrates what is possible when innovation in care delivery is paired with professionals that are passionate for patient safety and rigorous quality standards." This rigorous but flexible approach provides the assurance that moving CAR T-cell therapy into the community does not mean cutting corners on safety.

The Tennessee Blueprint: A Model for National Expansion

Tennessee Oncology’s achievement serves as the crucial proof-of-concept for this new paradigm. As part of the OneOncology network, the practice has demonstrated that with the right investment, partnerships, and commitment, high-quality cellular therapy delivery is achievable in a community-based, clinic-first model. Their journey provides a blueprint for other practices nationwide.

"Becoming the first community oncology practice to earn FACT accreditation is significant and reflects our unwavering commitment to advancing clinical research and delivering the highest standard of care to patients receiving cellular therapy," said Michael Byrne, DO, Cellular Therapy Program Director at Tennessee Oncology. His statement underscores the pride and dedication required to navigate the demanding accreditation process.

This is not a standalone effort. The practice's partner, OneOncology, has been a key enabler. "Tennessee Oncology's FACT accreditation is a milestone for community oncology," said Davey Daniel, MD, Chief Medical Officer at OneOncology. "It proves that high-quality CAR-T delivery is achievable outside the academic setting." Crucially, Dr. Daniel also announced a clear path forward: "we look forward to supporting four additional OneOncology practices as they pursue accreditation." This commitment, backed by OneOncology's significant investment of over $58 million in practice enhancements in 2024 alone, transforms a single achievement into a scalable strategy. The path is now illuminated for other community oncology networks to follow.

The Ripple Effect: An Evolving Ecosystem

The accreditation of Tennessee Oncology is the first domino to fall in what is expected to be a cascade of change across the cancer care ecosystem. With six other community programs already in the FACT accreditation pipeline as of this summer, the momentum is building. This expansion will create a more resilient and distributed network of treatment centers, a critical development for meeting the growing demand for cellular therapies.

For pharmaceutical companies that manufacture these multi-million-dollar treatments, a broader network of accredited sites means their therapies can reach more patients, expanding their market and impact. For referring oncologists, many of whom have felt underequipped to discuss cellular therapy according to recent surveys, having local, trusted partners to send patients to will be transformative. It empowers them to have more meaningful conversations about advanced treatment options.

FACT's role remains central to ensuring this expansion is both successful and safe. The organization’s three-year re-accreditation cycle and emphasis on continuous quality management ensure that standards will not slip as the number of centers grows. By establishing a clear, safe, and reproducible pathway for community practices, FACT is not just opening a door; it is engineering a fundamental and necessary evolution in how we deliver the most advanced weapons against cancer.